Lexeo Therapeutics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
345 Park Avenue South Fl 6, New York Cit...Phone Number
(212) 547-9879Website
www.lexeotx.comRevenue
$12.9 MillionStock Symbol
LXEOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Lexeo Therapeutics
Based out of New York City, NY, Lexeo Therapeutics is a biotechnology company with a focus on genetic medicines and rare diseases.Explore more
Lexeo Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
HD
Vice President, Late-Stage Cardiology Develop...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lexeo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Lexeo Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Lexeo Therapeutics
Product Launch: Get notified when Lexeo Therapeutics launches new products
Check if Lexeo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Lexeo Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Lexeo Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Lexeo Therapeutics had a recent Job posting/layoffs
Lexeo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Lexeo Therapeutics
Compare insights from companies similar to Lexeo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lexeo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lexeo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lexeo Therapeutics.
Lexeo Therapeutics financials insights
Gather financial insights about Lexeo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$85M
Series B
$100M
2023
Stock Offering
$100M
2024
Share Placement
$95M
2025
Stock/Share Issuance
$80M
Lexeo Therapeutics Tech Stack
A closer look at the technologies used by Lexeo Therapeutics
Most Recent Scoops
Project
reported that interim clinical data for LX2006 shared at ASGCT demonstrated statistically significant improvements in mean mFARS scores for LX2006-treated participants in the phase I/II studies compared to a propensity-matched control cohort from the UNIFAI natural history study, with an annualized difference in progression of 2.3 points per year and treatment benefit observed regardless of background use of SKYCLARYS.
Clinical Operations
Project
Lexeo Therapeutics has designed LX2006 to address the root cause of Friedreich's ataxia by restoring frataxin, delivering a functional full-length copy of the frataxin gene via an AAVrh10 vector with a natural affinity for cardiomyocytes, enabling efficient cardiac targeting at relatively lower doses. The therapy also incorporates a CAG promoter to drive frataxin expression beyond the heart, including in skeletal muscle and potentially in the dorsal root ganglia.
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Lexeo Therapeutics News & Media
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studiesLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial designLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 2:35 p.m. ET in New York, NY.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lexeo Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of New York City, NY, Lexeo Therapeutics is a biotechnology company with a focus on genetic medicines and rare diseases.... Read More
